Search Results - "Harrer, A."

Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death‐1 therapies and lessons learned from natalizumab by Harrer, A., Lang, R., Kölblinger, P.

Get full text

Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events by O´Sullivan, C., Zach, F., Moser, T., Pilz, G., Harrer, A., Trinka, E., Enzinger, C., Pfaff, J. A. R., Wipfler, P.

Get full text

4.3 μm quantum cascade detector in pixel configuration by Harrer, A, Schwarz, B, Schuler, S, Reininger, P, Wirthmüller, A, Detz, H, MacFarland, D, Zederbauer, T, Andrews, A M, Rothermund, M, Oppermann, H, Schrenk, W, Strasser, G

“…We present the design simulation and characterization of a quantum cascade detector operating at 4.3μm wavelength. Array integration and packaging processes…”
Get full text

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy by Harrer, A, Tumani, H, Niendorf, S, Lauda, F, Geis, C, Weishaupt, A, Kleinschnitz, C, Rauer, S, Kuhle, J, Stangel, M, Weber, F, Uhr, M, Linnebank, M, Wildemann, B, Jarius, S, Guger, M, Ayzenberg, I, Chan, A, Zettl, U, Wiendl, H, Pilz, G, Hitzl, W, Weber, JR, Kraus, J

“…Recently, the disappearance of oligoclonal bands (OCBs) from the cerebrospinal fluid (CSF) of a few natalizumab-treated patients with multiple sclerosis (MS)…”
Get full text

Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine by Radlberger, RF, Sakic, I, Moser, T, Pilz, G, Harrer, A, Wipfler, P

“…•Relapsing remitting multiple sclerosis•Cladribine•memory B cells•hyperrepopulation•immune phenotyping, disease activity Background: Recent data support a key…”
Get full text

High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis by Harrer, A., Pilz, G., Wipfler, P., Oppermann, K., Sellner, J., Hitzl, W., Haschke‐Becher, E., Afazel, S., Rispens, T., van der Kleij, D., Trinka, E., Kraus, J.

“…Summary Strongly decreased leucocyte counts and a reduced CD4/CD8 T cell ratio in the cerebrospinal fluid (CSF) of natalizumab (NZB)‐treated multiple sclerosis…”
Get full text

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? by Wipfler, P., Harrer, A., Pilz, G., Oppermann, K., Afazel, S., Haschke-Becher, E., Sellner, J., Trinka, E., Kraus, J.

“…Background More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal…”
Get full text

Glatiramer acetate attenuates the pro‐migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis by Sellner, J., Koczi, W., Harrer, A., Oppermann, K., Obregon‐Castrillo, E., Pilz, G., Wipfler, P., Afazel, S., Haschke‐Becher, E., Trinka, E., Kraus, J.

“…Summary An altered expression pattern of adhesion molecules (AM) on the surface of immune cells is a premise for their extravasation into the central nervous…”
Get full text

Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis by Wipfler, P., Heikkinen, A., Harrer, A., Pilz, G., Kunz, A., Golaszewski, S. M., Reuss, R., Oschmann, Patrick, Kraus, J.

“…Inflammatory serum parameters are intensely investigated in the search of biomarkers for disease activity and treatment response in multiple sclerosis (MS). A…”
Get full text

Metafora: A Web-Based Platform for Learning to Learn Together in Science and Mathematics by Dragon, T., Mavrikis, M., McLaren, B. M., Harrer, A., Kynigos, C., Wegerif, R., Yang Yang

“…This paper presents Metafora, both a platform for integrated tools as well as an emerging pedagogy for supporting Learning to Learn Together in science and…”
Get full text

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment by Wipfler, P, Oppermann, K, Pilz, G, Afazel, S, Haschke-Becher, E, Harrer, A, Huemer, M, Kunz, A, Golaszewski, S, Staffen, W, Ladurner, G, Kraus, J

“…Background: Natalizumab is the first monoclonal antibody therapy approved for multiple sclerosis (MS). Its therapeutic mechanism is the blockade of the…”
Get full text

Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies by Pilz, G, Harrer, A, Oppermann, K, Wipfler, P, Golaszewski, S, Afazel, S, Haschke-Becher, E, Trinka, E, Kraus, J

“…Natalizumab is a humanized monoclonal antibody directed against the alpha-4 integrin subunit of very late activation antigen-4 (VLA-4). Natalizumab…”
Get full text

Natalizumab saturation: Biomarker for individual treatment holiday after natalizumab withdrawal? by Wipfler, P, Harrer, A, Pilz, G, Oppermann, K, Haschke-Becher, E, Afazel, S, Sellner, J, Trinka, E, Kraus, J

Get full text

Tumefactive MS lesions under fingolimod: A case report and literature review by Pilz, G, Harrer, A, Wipfler, P, Oppermann, K, Sellner, J, Fazekas, F, Kraus, J, Trinka, E

Get full text

Reduced intrathecal IgG synthesis in the cerebrospinal fluid from natalizumab-treated patients with active multiple sclerosis by Harrer, A, Pilz, G, Wipfler, P, Oppermann, K, Holl, B, Hitzl, W, Afazel, S, Haschke-Becher, E, Trinka, E, Kraus, J

Get full text

Flow-cytometry and the detection of anti-natalizumab NAB in multiple sclerosis by Oppermann, K, Harrer, A, Pilz, G, Wipfler, P, Holl, B, Deisenhammer, F, Afazel, S, Haschke-Becher, E, Trinka, E, Kraus, J

Get full text

Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy by Broussalis, E., Hutterer, M., Oppermann, K., Wipfler, P., Pilz, G., Harrer, A., Haschke-Becher, E., Golaszewski, S., Schönauer, U., Weis, S., Killer-Oberpfalzer, M., Mc Coy, M., Trinka, E., Kraus, J.

“…Background The diagnosis of the isolated leptomeningeal involvement of a primary central nervous system B‐cell lymphoma without parenchyma lesions may be…”
Get full text

High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) – A pilot study by Hegen, H, Guger, M, Harrer, A, Hoelzl, M, Kraus, J, Skrobal, A, Schautzer, F, Schmidegg, S, Schocke, M, Deisenhammer, F

“…Abstract Background Neutralizing antibodies (NAb) against interferon-beta (IFNβ) affect its treatment efficacy. So far, there are no anti-NAb strategies…”
Get full text

P06.19.A BEYOND T CELL TOXICITY - INTRATHECAL CXCL13 ELEVATION INDICATES B-CELL INVOLVEMENT IN NEUROLOGICAL IMMUNE-RELATED ADVERSE EVENTS FOLLOWING IMMUNE CHECKPOINT INHIBITION: 2 CASE OBSERVATIONS AND COMPREHENSIVE REVIEW by Bieler, L, Otto, F, Seiberl, M, Moser, T, Kleindienst, W, Wipfler, P, Kölblinger, P, Harrer, A

“…Abstract BACKGROUND Neurological immune-related adverse events (nirAE) can occur following cancer treatment with immune checkpoint inhibitors (ICI). Mainly…”
Get full text

Immune Tolerance Induction with High-Dose Intravenous Interferon-beta in Multiple Sclerosis Patients with Neutralizing Antibodies - A Pilot Study (P04.121) by Hegen, H., Guger, M., Harrer, A., Hoelzl, M., Kraus, J., Skrobal, A., Schautzer, F., Schmidegg, S., Deisenhammer, F.

“…Abstract only…”
Get full text